Radiation boost may buy more time for breast cancer patients
NCT ID NCT06882499
First seen Apr 09, 2026 · Last updated May 24, 2026 · Updated 9 times
Summary
This study looks at whether adding a precise, high-dose radiation treatment called SABR to ongoing hormone therapy and CDK 4/6 inhibitors can delay the need to switch to a new cancer treatment in people with ER-positive, HER2-negative advanced breast cancer. About 74 participants whose cancer has started to grow in a few spots while on first-line therapy will be randomly assigned to receive either SABR plus their current drugs or a new standard drug treatment chosen by their doctor. The goal is to see if the radiation approach keeps the cancer under control longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.